Home / Top News / SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Decision Diagnostics Corp. (DECN) and Encourages DECN Investors to Contact the Firm
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Decision Diagnostics Corp. (DECN) and Encourages DECN Investors to Contact the Firm
PHILADELPHIA, Dec. 19, 2020 (GLOBE NEWSWIRE) Kaskela Law LLC announces that it is investigating Decision Diagnostics Corp. (“Decision Diagnostics”) (OTC: DECN) on behalf of the company’s stockholders.
On December 17, 2020, the U.S. Securities and Exchange Commission (“SEC”) filed a complaint against Decision Diagnostics and its Chief Executive Officer (“CEO”), Keith Berman, in the U.S. District Court for the Southern District of New York. The complaint alleges that Decision Diagnostics and Berman seized upon the Covid-19 global pandemic through a series of press releases that falsely claimed Decision Diagnostics had developed a finger prick blood test that coul
DECN Comments on Recent Legal Filings by Federal Agencies – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
CEO charged in alleged COVID-19 fraud scheme MarketWatch 12/19/2020 Claudia Assis © Thomson Reuters A vial of the Pfizer vaccine against the coronavirus disease (COVID-19) used at The Reservoir nursing facility is shown in West Hartford, Connecticut, U.S., December 18, 2020. Stephen Dunn/Pool via REUTERS
The Justice Department said late Friday that a federal grand jury has indicted a California chief executive for allegedly concocting a scheme to defraud investors with false claims about a COVID-19 test.
Popular Searches
That led to millions of dollars in investors losses, the DOJ said. Keith Berman, 67, the CEO of Decision Diagnostics Inc. was charged with one count of securities fraud and one count of making false statements, the DOJ said.
December 18, 2020 On Thursday in the Southern District of New York, the Securities and Exchange Commission (SEC) filed a complaint against Keith Berman and Decision Diagnostics Corp. (DECN), alleging that the defendants made false and misleading public statements in the spring that they had developed a “break-through” finger-pricking device to test for the novel coronavirus when they actually had not finished the product nor even developed a prototype.
In mid-February, Berman, president and CEO of biotechnology company DECN, learned of the location of DECN’s manufacturing site for its glucose testing strip for diabetes and decided to pursue the development of a coronavirus testing kit the first time the company had attempted to create a virus detection test according to the complaint.
Decision Diagnostics Corp.: DECN Comments on Recent Legal Filings by Federal Agencies
LOS ANGELES, CA / ACCESSWIRE / December 18, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) www.decisiondiagnostics.co, a leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters through its subsidiary Pharma Tech Solutions, Inc., as well as the designer and manufacturer of the GenViro! Covid-19 Swift Kit testing kits, hereby confirms two recent legal filings by separate agencies of the Federal government regarding DECN and its CEO Keith Berman concerning its GenViro! Covid-19 testing products.
Keith Berman, the CEO of DECN, was charged yesterday in Los Angeles by the United States Department of Justice with one count of securities fraud and one count of making a false statement to government officials. It is alleged that Mr. Berman made false and misleading statements in connection with DECN s effort to develop, test and obtain regula
vimarsana © 2020. All Rights Reserved.